Coronavirus (COVID-19) Current Therapy Market Definition

The coronavirus (COVID-19) current therapy market consists of sales of drugs and related services by entities (organizations, sole traders and partnerships) that are currently used for the treatment of COVID-19 infection. Coronavirus (COVID-19) current therapy includes repurposed single-drug therapeutics and combination drug therapeutics used in treating COVID-19 patients. The coronavirus (COVID-19) current therapy market consists of revenue generated by the companies that manufacture coronavirus current therapeutics by the sales of these products which are used in hospitals and clinics, home care, diagnostic laboratories, and research institutions. Coronavirus disease (COVID-19) is defined as illness caused by a novel coronavirus. Currently, the U.S. Food and Drug Administration (FDA) has approved the antiviral drug remdesivir (Veklury) to treat COVID-19 in hospitalized adults and children who are age 12 and older in the hospital. In addition to this, the FDA has also granted an emergency use authorization for the rheumatoid arthritis drug baricitinib (Olumiant) to treat COVID-19 in some cases and Baricitinib, a pill that works against COVID-19 by reducing inflammation and having antiviral activity. The FDA has also approved monoclonal antibody medications such as sotrovimab and a combination of two antibodies called casirivimab and imdevimab. Similarly, European Medicine Agency (EMA) approved monoclonal antibodies Regkirona (regdanvimab) and Ronapreve (casirivimab / imdevimab) for COVID-19 treatment.

Drugs For Immunotherapy Market Definition And Segments

Drugs for immunotherapy refer to a kind of medication that offers treatment to either stimulate or suppress the immune system to aid the body's protection against cancer, infection, and other disorders. Your immune system is assisted in fighting cancer via immunotherapy, a sort of cancer treatment. The body's immune system aids in the fight against infections and other disorders. The main types of drugs for immunotherapy are monoclonal antibodies, interferons, interleukins, vaccines, checkpoint inhibitors, and others. Monoclonal antibodies are created by cloning a single white blood cell. Every subsequent antibody generated in this manner may be traced back to a single parent cell. The different areas of therapy include cancer, autoimmune and inflammatory diseases, infectious diseases, and others, and they are used by various sectors such as hospitals and clinics, ambulatory surgical centers, and others. The drugs for immunotherapy market covered in this report is segmented – 1) By Type: Monoclonal Antibodies, Interferons, Interleukins, Vaccines, Checkpoint Inhibitors, Other Types 2) By Therapy Area: Cancer, Autoimmune & Inflammatory Diseases, Infectious Diseases, Other Therapy Areas 3) By End User: Hospitals & Clinics, Ambulatory Surgical Centers, Other End Users The drugs for immunotherapy market size has grown rapidly in recent years. It will grow from $255.14 billion in 2023 to $281.43 billion in 2024 at a compound annual growth rate (CAGR) of 10.3%. The growth in the historic period can be attributed to the rising incidence of cancer, unmet medical needs, cancer immunotherapy awareness, higher adoption rates of immunotherapeutic approaches, and rising investment by pharmaceutical giants. The drugs for immunotherapy market size are expected to see rapidly grown in the next few years. It will grow to $445.12 billion in 2028 at a compound annual growth rate (CAGR) of 12.1%. The growth in the forecast period can be attributed to combination therapies, personalized medicine, global expansion, biomarker-driven therapies, and increasing clinical trials. Major trends in the forecast period include advancements in immunology, advancements in car-t cell therapies, targeted immunotherapies, immunotherapy combinations, and neoantigen vaccines.

Rising Incidences Of Cancer In Drugs For Immunotherapy Market

The drugs for immunotherapy market are being driven by rising incidences of cancer globally. The major causes of most cancers include obesity, smoking, alcohol, and improper eating habits. For instance, in October 2022, Macmillan Cancer Support, the largest UK-based healthcare charity organization, it is estimated that there will be 3.5 million people with cancer by 2025, 4 million by 2030, and 5.3 million by 2040. Breast, lung, colon, rectum, and prostate cancers are the most prevalent types of cancer. The use of tobacco, having a high body mass index, drinking alcohol, eating few fruits and vegetables, and not exercising account for about one-third of cancer-related fatalities. The rising incidences of cancer are expected to increase the demand for immunotherapy drugs driving the drugs for immunotherapy market growth.

Increasing Healthcare Expenditure In Drugs For Immunotherapy Market

The increasing healthcare expenditure is anticipated to propel the growth of the drugs for immunotherapy market going forward. Healthcare expenditure refers to the entire amount of money spent on healthcare goods and services within a certain region or country over a specified period, which includes spending on doctor visits, hospital stays, surgeries, diagnostic procedures, and treatments. Health care expenditure such as financial resources is allocated by individuals, healthcare providers, insurance companies, and government agencies to cover the costs associated with drugs for immunotherapy and treatments. For instance, in May 2023, The Office for National Statistics, a UK-based government department, The UK had an increase in healthcare spending of 9.4% in nominal terms and 9.7% in real terms. In the UK, total healthcare spending in 2021 was $367.25 billion (£280.7 billion), pharmaceutical spending was $51.84 billion (£39.6 billion), and preventative care spending more than doubled from the previous year to $45.93 billion (£35.1 billion). Therefore, the increasing healthcare expenditure is driving the growth of the drugs for immunotherapy market. Major companies operating in the drugs for immunotherapy market include F. Hoffmann-La Roche Ltd., Novartis AG, Amgen Inc., AbbVie Inc., Merck & Co. Inc., GlaxoSmithKline PLC, Eli Lilly and Company, Bristol-Myers Squibb, AstraZeneca PLC, Johnson & Johnson, UbiVac, Pfizer Inc., Sanofi SA, Bayer AG, Celgene Corporation, Incyte Corporation, Juno Therapeutics Inc., Bluebird bio, Celldex Therapeutics, BeiGene, BioNTech AG, CytomX Therapeutics, Eisai Co. Ltd., Flexus Biosciences Inc., Genscript Biotech Corporation, Gilead Sciences Inc., Harpoon Therapeutics Inc., Heptares Therapeutics Ltd., Ignyta Inc., Immatics Biotechnologies, Jounce Therapeutics Inc.

Challenges In The Immunotherapy Market

The high cost of drugs for the immunotherapy market is acting as a restraint on the drugs for the immunotherapy market as a smaller number of patients can afford the treatment. Immunotherapy drugs are expensive as they are made specifically for each patient, and investment costs in research and development are high. For instance, Novartis’ Kymriah and Gilead Sciences’ Yescarta are two immunotherapy treatments that cost between $373,000 and $475,000 per patient, depending on the type of cancer. The Yervoy (ipilimumab) drug from Bristol-Myers Squibb, for the treatment of melanoma, a type of skin cancer, costs $120,000 per course of treatment. The high cost of immunotherapy drugs makes them unaffordable, thereby affecting the drugs for immunotherapy market growth.

Innovation In Drugs For Immunotherapy Market

Major companies operating in the drugs for immunotherapy market are focusing on innovating new products, such as Keytruda (pembrolizumab), to provide reliable services to customers. Keytruda (pembrolizumab) is a type of immunotherapy with a targeted therapy drug called an immune checkpoint inhibitor for adult patients. For Instance, In January 2023, Merck & Co., Inc., a US-based pharmaceutical company, launched Keytruda (pembrolizumab), which was approved by the Food and Drug Administration, a US-based federal agency. Keytruda (pembrolizumab) immunotherapy is used to treat various types of cancer by working with the immune system to help fight cancer cells. KEYTRUDA (pembrolizumab) is approved as an adjuvant treatment for non-small cell lung cancer (NSCLC). This is a significant development in the field of cancer treatment, and it is expected to have a positive impact on the healthcare industry.

Illumina Inc. And Bristol-Myers Squibb Partnership

Manufacturers of drugs for immunotherapy market are increasingly collaborating or partnering with other companies to share technology, resources, and product knowledge and expand the business. For example, Illumina Inc. and Bristol-Myers Squibb (BMS) collaborated to utilize Illumina’s next-generation sequencing (NGS) technology to develop and commercialize in-vitro diagnostic (IVD) assays in support of Bristol-Myers Squibb's oncology portfolio. Allogene Therapeutics Inc. and Pfizer Inc. entered into an asset contribution agreement to use Pfizer’s portfolio of assets related to allogeneic CAR-T therapy.

Pfizer Inc. Acquired Trillium Therapeutics

In November 2021, Pfizer Inc., a US-based Pharmaceutical industry company, acquired Trillium Therapeutics for $2.22 billion. With this acquisition, Pfizer Inc. aims to expand its oncology portfolio with the addition of next-generation, investigational immuno-therapeutics for hematological malignancies. Trillium Therapeutics is a Canada-based Biotech company that provides drugs for immunotherapy. North America was the largest region in the immunotherapy market in 2023. Middle East is expected to be the fastest growing region in the drug for immunotherapy market report during the forecast period. The regions covered in the drugs for immunotherapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the drugs for immunotherapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada. The drugs for immunotherapy market consist of sales of cytokines, CAR T-cell therapy, and cancer treatment vaccines. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The drugs for immunotherapy market research report is one of a series of new reports from The Business Research Company that provides drugs for immunotherapy market statistics, including drugs for immunotherapy industry global market size, regional shares, competitors with drugs for immunotherapy market share, detailed drugs for immunotherapy market segments, market trends and opportunities, and any further data you may need to thrive in the drugs for immunotherapy industry. This drug for immunotherapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Multiple Sclerosis Drugs Market Definition And Segments

Multiple Sclerosis drug refers to medications that are designed to stop the progression of disability and disease relapses. These medications are referred to as ‘disease-modifying treatment’. These drugs target a protein on the surface of immune cells and reduce the number of white blood cells to help prevent MS relapses. The white blood cells' propensity for nerve injury may be reduced by this impact. The main drug classes of multiple sclerosis drugs is immunomodulators, immunosuppressants, interferons, and others. Immunomodulators are a class of drugs that primarily target pathways involved in the treatment of multiple myeloma and a few other cancers. The various routes of administration include oral drugs and parenteral drugs that are distributed through hospital pharmacies, retail pharmacies, and online stores. The multiple sclerosis drugs market covered in this report is segmented – 1) By Drug Class: Immunomodulators, Immunosuppressants, Interferons, Other Drug Classes 2) By Distribution Channels: Hospital Pharmacy, Retail Pharmacy, Online Stores 3) By Route Of Administration: Oral Drugs, Parenteral Drugs The multiple sclerosis drugs market size has grown strongly in recent years. It will grow from $29.66 billion in 2023 to $31.5 billion in 2024 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to rising prevalence of multiple sclerosis, unmet medical need, rising investments from pharmaceuticals, growing awareness of multiple sclerosis. The multiple sclerosis drugs market size is expected to see strongly grown in the next few years. It will grow to $47.97 billion in 2028 at a compound annual growth rate (CAGR) of 11.1%. The growth in the forecast period can be attributed to increasing availability of clinical trials, targeted therapy, growing focus on preventive medicine, growing demand for biosimilars, expanding geographical reach, combination therapies. Major trends in the forecast period include immunomodulatory and immunomodulatory drugs, long-acting formulations, patient-centric care, drug innovation, oral and infusion therapies.

Government And Non-Government Support Fueling Growth Of Multiple Sclerosis Drugs Market

The growth of the multiple sclerosis drugs market is aided by support from the government as well as non-government organizations. The government and non-government organizations fund several schemes and programs to offer their support to enhance the quality of life of people affected with multiple sclerosis (MS). For instance, the government of Alberta in partnership with the Department of Economic Development, Trade, and Tourism in Canada invested $1 million towards the Canadian Prospective Cohort Study to Understand Progression in Multiple Sclerosis (CanProCo) to support the research and innovations to enhance understanding and treatment for MS disease. CanProCo is an initiative to consolidate the efforts of nearly 50 MS researchers from various disciplines across Canada. The initiative was further funded by the Canada Brain Research, Biogen Canada, and the MS Society of Canada, as well as Hoffmann-La Roche Limited (Roche Canada) to raise a total of $10 million. Appropriate financial support from the government and non-government organizations boosts the growth of the multiple sclerosis drugs market.

Increasing Prevalence Of Multiple Sclerosis

The increasing prevalence of multiple sclerosis is expected to drive the growth of the multiple sclerosis drug market going forward. Multiple sclerosis (MS) is a chronic and often disabling autoimmune disease that affects the central nervous system (CNS). Multiple sclerosis drugs are pharmaceuticals designed to manage and treat the symptoms and progression of multiple sclerosis (MS). These drugs can help alleviate symptoms, reduce relapses, slow the disease's progression, and improve the quality of life for individuals living with MS. For instance, in May 2023, according to an article published by Pace Hospitals, an India-based hospital, there are about 2.8 million MS patients worldwide, i.e. 35.9 per 100,000 population. The annual incidence rate in 75 reporting countries stands at 2.1 cases per 100,000 individuals, with an average age of diagnosis at 32 years. It exhibits a higher prevalence among females compared to males. Therefore, the increasing prevalence of multiple sclerosis will continue to drive the growth of the multiple sclerosis drug market. Major companies operating in the multiple sclerosis drugs market include Biogen Inc., Novartis International AG, F. Hoffmann-La Roche Ltd., Bayer HealthCare LLC, Pfizer Inc., Merck & Co. Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline PLC, Acorda Therapeutics Inc., Actelion Pharmaceuticals Ltd., EMD Serono Inc., AbbVie Inc., Bayer Schering Pharma AG, CinnoVex, Rebif, Bristol-Myers Squibb Company, Johnson & Johnson, Mallinckrodt Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, Mylan N.V., Opexa Therapeutics Inc., Receptos Inc., Synthon Pharmaceuticals Inc., TG Therapeutics Inc., Alexion Pharmaceuticals Inc., Alkermes PLC, Amgen Inc., Apitope Technology (Bristol) Ltd., Atara Biotherapeutics Inc., Celgene Corporation, Genzyme Corporation

High Drug Prices Constrain Growth Of Multiple Sclerosis Drugs Market

The high cost of drugs to treat multiple sclerosis (MS) restricts the growth of the multiple sclerosis drugs market. MS is a cureless disease with a high chance of disability and requires lifelong treatment. Despite the heavy competition among the drug companies, the cost of MS drugs is high, increasing the overall cost of treatment. The companies operating in the multiple sclerosis drugs market often have to work towards reducing the cost of these drugs to justify their cost-effectiveness to their consumers. As reported by the Institute for Clinical and Economic Review (ICER), MS drugs cost roughly between $63,000 and $104,000 annually. For instance, after receiving criticism from the National Multiple Sclerosis Society on the high price of Vumerity, a drug to treat relapse MS, Biogen, and Alkermes had to reduce the prices of the drug to $88,000 per year to make it affordable to the patients. The high cost of drugs, which are required lifelong negatively affects the growth of the multiple sclerosis drugs market.

Increasing Focus On New Product Launches To Meet Growing Demand For MS Drugs

The companies are rapidly intensifying their efforts to focus on new product launches to cater to the rising demands for MS drugs. Multiple sclerosis requires lifelong treatment, which increases the overall cost of treating a patient. To provide better and more effective treatment companies in the multiple sclerosis market are developing drugs specific to the treatment of multiple sclerosis. Following the trend, the FDA approved Novartis’ Mayzent (siponimod) and EMD Serono’s Mavenclad (cladribine) for the treatment of relapsing-remitting multiple sclerosis (RRMS), and active secondary progressive multiple sclerosis (SPMS). Both drugs were launched as easy-to-consume oral drugs.

Innovative Products And Competitive Strategies In The Multiple Sclerosis Drug Market

Major companies operating in the multiple sclerosis drug market are introducing innovative products such as Aidaptus auto-injector platform to gain a competitive edge in the market. The Aidaptus auto-injector platform is engineered to simplify operations and offer a versatile solution for pharmaceutical and biotechnology firms engaged in the development of diverse drug formulations including multiple sclerosis, intended for subcutaneous delivery. For instance, in September 2021, Owen Mumford, a UK-based medical device manufacturer launched Aidaptus auto-injector platform that was created for the administration of a wide range of drugs and biologics that require subcutaneous delivery. Aidaptus is a dual-purpose auto-injector, powered by a two-step spring mechanism, capable of accommodating both 1mL and 2.25 mL prefilled glass syringes within a single base device due to its versatile design that is designed to treat multiple sclerosis and other diseases.

Bristol-Myers Squibb Acquired Celgene

Bristol-Myers Squibb, a pharmaceutical company based in the United States, paid $74 billion for Celgene. Through the acquisition, Bristol-Myers Squibb aims to increase its product portfolio by utilizing the existing products of Celgene along with its technical and pipeline support. Ozanimod is one of Celgene’s pipeline drugs for the treatment of relapsing multiple sclerosis. The drug is currently in phase III clinical trials to be approved by the FDA. Celgene is a pharmaceutical company based in the United States that develops and markets medicines for cancer and inflammatory diseases such as multiple sclerosis. North America was the largest region in the global multiple sclerosis drug market in 2023. The Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the multiple sclerosis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the multiple sclerosis drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada. The multiple sclerosis drug market consists of sales of lemtrada, novantrone, ocrevus, and tysabri. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The multiple sclerosis drugs market research report is one of a series of new reports from The Business Research Company that provides multiple sclerosis drugs market statistics, including multiple sclerosis drugs industry global market size, regional shares, competitors with a multiple sclerosis drugs market share, detailed multiple sclerosis drugs market segments, market trends and opportunities, and any further data you may need to thrive in the multiple sclerosis drugs industry. This multiple sclerosis drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The dermatology drugs market consists of sales of dermatology drugs by entities (organizations, sole traders and partnerships) that produce dermatology drugs to treat skin diseases. This industry includes establishments that produce drugs to treat diseases such as rosacea, dermatitis, hyperhidrosis, androgenic alopecia, acne drugs, microbial infections and other skin disorders. The main types of dermatology drugs are acne drugs, dermatitis, psoriasis, and other drugs for dermatology diseases. Psoriasis is a skin condition that causes red, itchy scaly patches on the knees, elbows, trunk, and scalp. Hypolipidemic drugs are a diverse class of medications used to treat high levels of fats (lipids) in the blood, such as cholesterol (hyperlipidemia). The drugs are administered through oral, parenteral, and others that are classified into branded and generic drugs. The various mode of purchase includes prescription-based drugs and over-the-counter drugs which are distributed by hospital pharmacies, retail pharmacies/ drug stores, and others. The global dermatology drugs market size is expected to grow from $49.55 billion in 2021 to $54.54 billion in 2022 at a compound annual growth rate (CAGR) of 10.1%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The dermatology drugs market is expected to reach $117.82 billion in 2026 at a CAGR of 21.2%. The dermatology drugs market was mainly driven by rapid growth in emerging markets in the historic period. Emerging markets growth was aided by rising disposable income, stable political environment and increasing foreign investments in these countries. For instance, according to the IMF, China’s GDP growth rate was 2.3% in 2020. Additionally, according to the World Economic Outlook Reports by the IMF, the global growth is 6% in 2021 and expected to be 4.4% in 2022. Thus, strong economic growth boosted the demand for dermatology drugs and this drove the market during the historic period. High costs associated with drugs is a major issue faced by citizens of many countries. Pressure to contain costs and demonstrate value is widespread. Political uncertainty and persistent economic stress in numerous countries are calling into question the sustainability of public health care funding. In less wealthy countries, lack of cost-effective drugs has influenced the health conditions of the population and has led to a low average life expectancy. As a result, in countries such as Chad, Macedonia, Serbia, the pharmaceutical companies are faced with the pressure of reducing the price of drugs. The high costs associated with drugs are putting pressure on the revenues of dermatology drugs manufacturers. Drug manufacturing companies are using genome testing (genetic diagnosis) to reduce the time and costs spent in clinical trials. A clinical trial is a complex process and it often takes months for a drug to be available in the market. This deprives patients of cost-effective treatment. Researchers in the Rockefeller University used genomic testing and data analytics to predict the response of psoriasis patients for a given treatment. Genomic testing algorithms collect gene-expression data from skin biopsies and detect activity in 50,000 different genes. This technique can predict the response of a patient with an accuracy of 95% and within 12 weeks, thus saving significant time for clinical trials and the launch of new drugs. Major companies in the dermatology drugs market include Amgen, Reckitt Benckiser Group plc, AbbVie, Galderma S.A., LEO Pharma A/S, Bayer AG, GlaxosmithKline, Eli Lilly And Company, Novartis AG and Perrigo Company Plc. North America was the largest region in the dermatology drugs market in 2021. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the dermatology drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the dermatology drugs market report are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela and Vietnam. The global dermatology drugs market is segmented - 1) By Type: Acne Drugs, Dermatitis, Psoriasis, Other Drugs for Dermatology Diseases 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others 3) By Route of Administration: Oral, Parenteral, Others 4) By Drug Classification: Branded Drugs, Generic Drugs 5) By Mode of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs

The gastrointestinal drugs market consists of sales of gastrointestinal drugs by entities (organizations, sole traders and partnerships) that produce gastrointestinal drugs to treat gastrointestinal diseases such as ulcerative colitis, diverticular disease, perianal infections, anal fissures, hemorrhoids, constipation, and irritable bowel syndrome. The key gastrointestinal diseases drug categories include Anti-peptic agents (antacids, antagonists, Proton Pump Inhibitors, Sucralfate, and Misoprostol), antiemetics, adsorbents, anticholinergics, opiates, intestinal flora modifiers, emollient/surfactants, hyperosmotic, saline, and simulant/irritant. The main types of gastrointestinal drugs are antacids, antiulcerants, vitamin and minerals, antiobesity, antiemetics and antinauseants and antidiarrhoeals. Antacids are medications that counteract (neutralise) stomach acid to relieve indigestion and heartburn. The drugs are administered through oral, parenteral, and others that are classified into branded and generic drugs. The various mode of purchase includes prescription-based drugs and over-the-counter drugs which are distributed by hospital pharmacies, retail pharmacies/ drug stores and others. The global gastrointestinal drugs market size is expected to grow from $71.85 billion in 2021 to $75.63 billion in 2022 at a compound annual growth rate (CAGR) of 5.3%. The change in the gastrointestinal drugs market growth trend is mainly due to the companies stabilizing their output after catering to the demand that grew exponentially during the COVID-19 pandemic in 2020. The gastrointestinal drugs market is expected to reach $105.51 billion in 2026 at a CAGR of 8.7%. The aging population profile of most countries will contribute to the growth of the gastrointestinal drugs market. The increase in patient pool due to rising geriatric population globally, will contribute significantly to the growth of the market during the forecast period. According to the WHO, by 2030, one in every six people on the planet will be 60 or older. The proportion of the population aged 60 and up will rise from 1 billion in 2020 to 2.2 billion by 2050. This rise in the geriatric population increased the demand for medical care and drove the healthcare expenditure. This will led to increased demand for pharmaceuticals products, significantly impacting market growth during this period. During the forecast period, the growth of the gastrointestinal drugs market will be restrained by patent expiration of branded gastrointestinal drugs. In general, pharmaceutical companies invest a large sum of money in the drug development process and patents. During the patency period, the company holding the patent holds exclusivity for the manufacturing and distribution of drugs. Post expiration of patency, generic versions of the drugs are manufactured by other companies with prices much lower than the original branded drugs. Overall, this will negatively impact the growth of the market in terms of value. Major companies in the gastrointestinal drug industry are investing in making oral capsules of macromolecular drugs for gastrointestinal diseases for making the drug more effective. Macromolecular drugs, such as peptides, proteins, and antibodies, form a new class of drugs which can treat diseases of the gastrointestinal tract, such as inflammatory bowel disease. These macromolecular drugs are usually injected and only a fraction of the administered dose reaches the disease sites in the gastrointestinal tract. Thus, major companies such as Eli Lilly have been increasingly investing in making oral capsules for macromolecular drugs. The company invested $5 million to enter into a collaboration with Entrega to study the oral delivery of complex molecules, such as peptides to combat gastrointestinal diseases. Major companies in the gastrointestinal drugs market include Takeda Pharmaceuticals, Bayer AG, Abbott Laboratories, Otsuka Holdings Co ltd, Johnson & Johnson, Reckitt Benckiser Group plc, Bausch Health Companies Inc., Sanofi S.A, Procter & Gamble and Daiichi Sankyo Company. North America was the largest region in the gastrointestinal drugs market in 2021. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the gastrointestinal drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the gastrointestinal drugs market report are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela and Vietnam. The global gastrointestinal drugs market is segmented - 1) By Type: Antacids, Antiulcerants, Vitamin and Minerals, Antiobesity, Antiemetics and Antinauseants, Antidiarrhoeals 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others 3) By Route of Administration: Oral, Parenteral, Others 4) By Drug Classification: Branded Drugs, Generic Drugs 5) By Mode of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs

The hematology drugs market consists of sales of hematology drugs and related services by entities (organizations, sole traders and partnerships) that produce hematology drugs to treat diseases such as genetic disorders, anemia, and other related diseases. This industry includes establishments that produce blood products such as red blood cells, white blood cells, platelets, and fresh frozen plasma. It also consists of establishments which produce of anemia and other blood disorder drugs to treat anemia, hemophilia and blood clots. The main types of hermatology drugs are blood products, anemia and other blood disorder drugs. Any therapeutic substance derived from human blood is referred to as a blood product, which includes whole blood and other blood components for transfusion as well as plasma-derived medicinal products. The drugs are administered through oral, parenteral, and others that are classified into branded and generic drugs. The various mode of purchase includes prescription-based drugs and over-the-counter drugs which are distributed by hospital pharmacies, retail pharmacies/ drug stores, and others. The global hematology drugs market size is expected to grow from $33.06 billion in 2021 to $36.13 billion in 2022 at a compound annual growth rate (CAGR) of 9.3%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The hematology drugs market is expected to reach $73.67 billion in 2026 at a CAGR of 19.5%. The hematology drugs market growth is aided by stable economic growth forecasted in many developed and developing countries. The International Monetary Fund (IMF) stated that the global GDP growth rate was 3.3% in 2020 and 3.4% in 2021. Recovering commodity prices, after a significant decline in the historic period is further expected to aid the market growth. Developed economies are also expected to register stable growth during the forecast period. Additionally, emerging markets are expected to continue to grow slightly faster than the developed markets in the forecast period. This is expected to increase spending on healthcare services, thereby driving the demand for hematology drugs. Regulatory agencies and federal governments adopted stringent regulations and took a tough stance on drug pricing by pharmaceutical companies during the historic period. Pharmaceutical companies faced criticism from politicians, patients and physicians over high pricing of some medicines and drugs. Moreover, companies had to sell drugs and medicines at subsidized rates to government hospitals, doctors and clinics, further effecting companies’ revenues. This led to drug manufacturing companies operating on a reduced profit margin, which negatively impacted the attractiveness of the hematology drugs industry in the historic period. Tranexamic acid is increasingly being used to prevent postpartum hemorrhage (blood loss of over 500 ml or 1,000 ml within 24 hours of childbirth) due to its low price and wide availability. Tranexamic acid is an antifibrinolytic drug that helps in reducing bleeding in surgical and trauma patients, including women with postpartum hemorrhage. According to the World Maternal Antifibrinolytic (WOMAN) trial, using tranexamic acid within three hours of childbirth lowered death from bleeding by 31% and reduced the need for laparotomy (emergency bleeding control surgery) by 36%. The trial included over 20,000 women from 193 hospitals in 21 countries. Major companies in the hematology market include Amgen, Alexion Pharmaceuticals, Bayer AG, F. Hoffmann-La Roche Ltd., CSL, Takeda Pharmaceuticals, Novo Nordisk, Sanofi S.A, Daiichi Sankyo Company and Pfizer Inc. North America was the largest region in the hematology drugs market in 2021. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the hematology drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the hematology drugs market report are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela and Vietnam. The global hematology drugs market is segmented - 1) By Type: Blood Products, Anemia and Other Blood Disorder Drugs 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others 3) By Route of Administration: Oral, Parenteral, Others 4) By Drug Classification: Branded Drugs, Generic Drugs 5) By Mode of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs

The metabolic disorders drugs market consists of sales of metabolic disorders drugs and related services by entities (organizations, sole traders and partnerships) that produce metabolic disorders drugs to treat metabolic diseases. This industry includes establishments that produce drugs such as insulin, pramlintide and other drugs to treat diabetes, anti-thyroid drugs to treat hyperthyroidism, and other drugs to treat pituitary gland, adrenal gland and parathyroid gland disorders. The main types of metabolic disorders drugs are anti diabetics drugs, anti-thyroid drugs and others (hyperparathyroidism, hypopituitarism, hypoadrenalism). Antithyroid drugs are medications that either reduce thyroid hormone synthesis (thionamides) or increase thyroid hormone release (iodides). The drugs are administered through oral, parenteral, and others that are classified into branded and generic drugs. The various mode of purchase includes prescription-based drugs and over-the-counter drugs which are distributed by hospital pharmacies, retail pharmacies/ drug stores and others. The global metabolic disorders drugs market size is expected to grow from $82.05 billion in 2021 to $90.83 billion in 2022 at a compound annual growth rate (CAGR) of 10.7%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The metabolic disorders drugs market is expected to reach $205.11 billion in 2026 at a CAGR of 22.6%. The rise in sedentary jobs, busy lifestyles and changing consumer preferences are affecting the disease profile of the world population, especially non-communicable diseases such as diabetes and obesity. Long working hours, less physical activity, and unhealthy eating and drinking habits are major causes of metabolic disorders. According to the World Health Organization, chronic disease prevalence rose by 57% globally, in the year 2020. These factors are expected to increase the patient pool globally, thereby driving the metabolic disorders drugs market during the forecast period. Regulatory agencies and federal governments adopted stringent regulations and took a tough stance on drug pricing by pharmaceutical companies. Pharmaceutical companies faced criticism from politicians, patients and physicians over high pricing of some medicines and drugs. Moreover, companies had to sell drugs and medicines at subsidized rates to government hospitals, doctors and clinics, further effecting companies’ revenues. This led to drug manufacturing companies operating on a reduced profit margin. Such factors will negatively impact the attractiveness of the metabolic disorders drugs industry during the forecast period. Companies are focusing on employing artificial intelligence applications to revolutionize the treatment of metabolic disorders. Artificial Intelligence is a machine-based learning which makes use of human intelligence functionalities like reasoning and problem-solving abilities to obtain insights and provide useful information. This technology radically changes the treatment of metabolic syndrome by analyzing large sets of chemical and biological data to identify potential drug candidates with higher success rates and at a quicker pace when compared to human analysis. 3BIGS, a Korean biodata analysis-based company that studies the relation between diseases, targets and drugs is using AI technology to help researches repurpose the drugs for additional diseases. Major companies in the metabolic disorders drugs market include Novo Nordisk, Eli Lilly And Company, Novartis AG, Sanofi S.A, Merck & Co, GlaxosmithKline, Johnson & Johnson, AstraZeneca, Boehringer Ingelheim GmbH and Dainippon Sumitomo Pharma. North America was the largest region in the metabolic disorders drugs market in 2021. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the metabolic disorders drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the metabolic disorders drugs market report are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela and Vietnam. The global metabolic disorders drugs market is segmented - 1) By Type: Anti Diabetics Drugs, Anti-Thyroid Drugs, Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism) 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others 3) By Route of Administration: Oral, Parenteral, Others 4) By Drug Classification: Branded Drugs, Generic Drugs 5) By Mode of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs

The musculoskeletal disorders drugs market consists of sales of musculoskeletal disorders drugs and related services by entities (organizations, sole traders and partnerships) that produce musculoskeletal disorders drugs to treat musculoskeletal disorders such as arthritis, osteoporosis, osteomalacia, and other disorders. This industry includes establishments that produce drugs to treat rheumatoid arthritis, muscle relaxants to reduce muscle pain, and other drugs used in treating osteoarthritis, analgesics drugs, immunosuppressive. Some of the major drugs in the market include Piroxicam Glaxo, Dolonex, Felden, and Piroxicam Pfizer. The main types of musculoskeletal disorders drugs are drugs for rheumatoid arthritis, muscle relaxants and other musculoskeletal disorders drugs. A muscle relaxant is a medication that causes muscle contractions to cease. The drugs are administered through oral, parenteral, and others that are classified into branded and generic drugs. The various mode of purchase includes prescription-based drugs and over-the-counter drugs which are distributed by hospital pharmacies, retail pharmacies/ drug stores and others. The global musculoskeletal disorders drugs market size is expected to grow from $897.45 billion in 2021 to $104.03 billion in 2022 at a compound annual growth rate (CAGR) of 6.8%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The musculoskeletal disorders drugs market is expected to reach $163.94 billion in 2026 at a CAGR of 12%. The aging population profile of most countries contributed to the growth of the musculoskeletal disorders drugs market. The increase in patient pool due to rising geriatric population globally, contributed significantly to the growth of the market during the historic period. According to the WHO, by 2030, one in every six people on the planet will be 60 or older. The proportion of the population aged 60 and up will rise from 1 billion in 2020 to 2.1 billion by 2050. This rise in the geriatric population increased the demand for medical care and drove the healthcare expenditure. This has led to increased demand for pharmaceuticals products, significantly impacting market growth during this period. Regulatory changes are likely to lead to increased costs relating to new product development and service offerings to clients. These changes are related to data protection such as the European Union's General Data Protection Regulation (GDPR), changes to drug approval procedures and other regulatory changes. For instance, according to a study on 100 Data Privacy and Data Security statistics for 2020, GDPR compliance is a top priority for 58% of European companies. The GDPR regulation is a EU law on data protection and privacy of individuals residing the European Union and the European Economic Area (EEA). It also regulates data anonymization thus maintaining integrity of data dealing with patients and other clinical trial studies. The potential loss of revenue due to delays in product release and additional costs incurred due to stringent approval processes puts strain to investments relating to new product development, thereby affecting the growth of the musculoskeletal disorders drugs market. Going forward, the market for muscle relaxants is expected to increase with the rise in combination therapy. Combination therapy involves use of more than one medication or drug to treat a disease. These combinational therapies reduce the frequency of drug administration. For instance, in May 2019, Galt Pharmaceuticals has submitted a Supplemental Abbreviated New Drug Application to the U.S. Food and Drug Administration for Orphengesic Forte an oral formulation of aspirin, caffeine, and orphenadrine for the treatment of pain caused due to musculoskeletal disorders. Major companies in the musculoskeletal disorders drugs market include Sanofi S.A, Pfizer Inc., Bristol-Myers Squibb, Eli Lilly And Company, Mitsubishi Tanabe Pharma Corporation, Horizon Therapeutics plc, Procter & Gamble, Eisai Co. Ltd, Biogen Inc and Sino Biopharmaceutical. North America was the largest region in the musculoskeletal disorders drugs market in 2021. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the musculoskeletal disorders drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the musculoskeletal disorders drugs market report are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela and Vietnam. The global musculoskeletal disorders drugs market is segmented - 1) By Type: Drugs for Rheumatoid Arthritis, Muscle Relaxants, Other Musculoskeletal Disorders Drugs 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others 3) By Route of Administration: Oral, Parenteral, Others 4) By Drug Classification: Branded Drugs, Generic Drugs 5) By Mode of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs